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Abstract.  Transforming growth factor beta (TGF-/3) is 
released from cells in a latent form consisting of the 
mature growth factor associated with an aminoterminal 
propeptide and latent TGF-B binding protein (LTBP). 
The endogenous activation of latent TGF-B has been 
described in co-cultures of endothelial and smooth 
muscle cells. However, the mechanism of this activa- 
tion remains unknown. Antibodies to native platelet 
LTBP and to a peptide fragment of LTBP inhibit in a 
dose-dependent manner the activation of latent TGF-~ 
normally observed when endothelial cells are cocul- 
tured with smooth muscle cells. Inhibition of latent 
TGF-B activation was also observed when cells were 
co-cultured in the presence of an excess of free LTBP. 
These data represent the first demonstration of a func- 
tion for the LTBP in the extracellular regulation of 
TGF-B activity and indicate that LTBP participates in 
the activation of latent TGF-B,  perhaps by concentrat- 
ing the latent growth factor on the cell surface where 
activation occurs. 
T 
RANSFORMING growth factor-B (TGF-B)  1 is a mem- 
ber of a family of molecules, including MuUerian in- 
hibiting substance,  inhibins, activins, and bone mor- 
phogenic proteins that are potent regulators of cell growth 
and  development (Roberts  and Sporn,  1990; Lyons  and 
Moses,  1990; Massague,  1990). TGF-B has been isolated 
from a variety of tissues and has a broad spectrum of effects 
on many cell types. TGF-B stimulates the growth of cells of 
mesenchymal origin (Shipley et al.,  1985) and inhibits the 
growth  of epithelial  (Tucker  et  al.,  1984),  endothelial 
(Frater-Schroder et al., 1986), and lymphoid (Kerhl et al., 
1986a, b) cells. It induces matrix biosynthesis by stimulating 
the expression of matrix components, such as proteoglycans 
(Chert et al., 1987; Bassols and Massague,  1988), collagen 
and fibronectin (Ignotz et al., 1987; Raghow et ai., 1987), 
and protease inhibitors,  including plasminogen activator in- 
hibitor type 1 (P/d-l) (Laiho et al.,  1986; Pepper et ai., 
1990) and tissue inhibitor of metalloprotease (Edwards et 
al.,  1987) as well as decreasing the expression  of matrix 
degrading proteases  such as collagenase  (Edwards  et al., 
1987). TGF-/3 is chemotactic for fibroblasts (Postlewaite et 
al.,  1987), macrophages (Wahl et al.,  1987), and smooth 
muscle cells (Koyama et al., 1990), and inhibits the migra- 
tion of endotheliai cells (Heimark et al., 1986; Muller et al., 
1987; Sato and Rifldn, 1989). However, although it is clear 
1. Abbreviations used in this paper: BAE, bovine aortic endothelial; BS  3, 
bis(sulfosuceinimidyl)  suberate;  BSM,  bovine  smooth  muscle;  LAP, 
latency associated peptide; LTBP, latent TGF-/5  binding; PA, plasminogen 
activator; "I'GF-/~,  transforming growth factor-B. 
that TGF-/3 is an important molecule in regulating  many 
aspects of cellular physiology, it is not clear how the activity 
of this growth factor is controlled. 
One level of control that appears to be important is the ac- 
tivation of TGF-/3 from its latent form. TGF-~ is secreted 
from cells predominantly, if not exclusively, in a latent form 
that is unable to bind the TGF-B receptor and is inactive 
(Pircher et al.,  1986; Lawrence et al.,  1985). The latent 
TGF-B  molecule  is  synthesized  as  a  390-amino  acid 
pmpmtein that is processed at an arg-arg cleavage site be- 
tween residues 278  and 279. Mature TGF-B1 is  a  25-kD 
homodimer of l l2-amino acid polypeptides  derived from 
the carboxy terminus of the propmtein (Derynck et al., 
1985).  The latency associated  peptide (LAP) is a  75-kD 
homodimer of two 249-amino acid polypeptides represent- 
ing the NH2-terminai remnant of the proprotein.  These two 
proteins,  mature TGF-B and the LAP,  remain associated 
through noncovalent interactions.  The dissociation  of the 
LAP from mature TGF-B renders TGF-B biologically active. 
Yet, how this activation is mediated in vivo is unknown. 
A high molecular  weight form (,o210,000) of  latent TGF-/3 
has been identified  in platelets  (Miyazono  et al.,  1988; 
Wakefield et al.,  1988). This form of latent TGF-B was 
shown to contain a protein of ~160 kD that is joined to the 
LAP through a disulfide bond (Miyazono et al., 1988). The 
latent TGF-B binding  protein  (LTBP) has  recently been 
cloned and sequenced (Kanzaki et al.,  1990; Tsuji et al., 
1990). The protein contains several copies of motifs found 
in other proteins.  There are 16 EGF-like domains that, in 
other proteins,  have been reported to be involved in pro- 
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of these EGF-like domains contain hydroxyasparagine  post- 
translational  modifications (Kanzaki  et al.,  1990).  In addi- 
tion, the sequence contains an RGD and a laminin B2-1ike 
sequence. Both these sequences may mediate protein-pro- 
tein interactions with cell surface molecules such as inte- 
grins  (Ruoslahti  and  Pierschbacher,  1987;  Sasaki  and 
Yamada, 1987). However, the function of LTBP is not under- 
stood, although  it is known that the addition of LTBP does 
not confer latency on mature recombinant TGF-~I (Kanzaki 
et al.,  1990) and that LTBP may be required for the proper 
assembly and  secretion of latent  TGF-~ (Miyazono  et al., 
1991). 
Latent TGF-/3 in medium conditioned by cultured cells can 
be activated  by transient  treatment  with either acid,  base, 
heat, or chaotrophic agents  (Lawrence et al.,  1985).  Latent 
TGF-~ can also be activated either by proteolysis of the latent 
complex (Lyons et al., 1988,  1990) or by alteration of carbo- 
hydrate  structures  within the LAP (Miyazono and Heldin, 
1990).  In  addition  to  treatments  with  exogenous  agents, 
latent  TGF-/~ has been shown to be activated  when bovine 
aortic endothelial (BAE)  cells are co-cultured with bovine 
pericytes or bovine smooth muscle (BSM) cells (Antonelli- 
Orlidge et al.,  1989;  Sato and Rifkin,  1989;  Sato et al., 
1990).  The mechanism of this co-culture activation  is not 
well understood, but appears to involve plasmin because in- 
hibitors of plasmin prevent the activation  of latent TGF-/~ in 
co-cultures (Sato and Rifkin, 1989;  Sato et al., 1990).  The 
reaction also appears to be surface mediated (Sato and Rif- 
kin,  1990;  Dennis and Rifkin,  1991). 
To determine whether LTBP is involved in the activation 
of latent TGF-/~, we analyzed the effect of anti-LTBP antibod- 
ies, as well as competition with free LTBP, on the generation 
of TGF-/~ in co-cultures of BAE and BSM cells. The results 
indicate that the participation  of the LTBP is required for the 
activation  of latent TGF-/3 in this system. 
Materials and Methods 
Antibodies 
Anti-LTBP IgG was purified from a rabbit antiserum to native human plate- 
let LTBP (Ab 39; Kanzaki et al., 1990) using protein A-Sepharose (Phar- 
macia, LKB Biotechnology, Inc., Piscataway,  NJ). IgG purified from a rab- 
bit antiserum to a peptide corresponding to amino acids 1111-1122 of the 
sequence of LTGF (Kanzaki et al,. 1990) was also used. LTBP was purified 
from platelets as previously described (Miyazono et al.,  1988).  Fab frag- 
ments were generated by papain digestion of anti-LTBP antibody and iso- 
lated from the eluate following chromatography on a protein A-Sepharose 
column (Harlow and Lane,  1988). 
Crass-linking and Western Blot Analysis of 
Conditioned Media 
To prepare conditioned media, BAE and BSM cells were plated separately 
at a density of 15  x  106 cells per TI50 flask in r  containing 10% 
calf serum. Cells were incubated for 2 h to allow them to attach to the bot- 
tom of the flask and rinsed with serum-free c~MEM. They were then in- 
cubated with 10 ml of serum-free medium for 12 h. This medium was dis- 
carded and  replaced with  10  ml  per flask of fresh c~MEM containing 
aprotinin (1 ~g/ml), pepstatin (0.5/~g/ml), and leupeptin (0.5 ~g/ml) for 
24 h. Conditioned media were collected and clarified by cantrifugation at 
2,500 g  for 15 rain in tubes siliconized with Sigmacoat. Clarified condi- 
tioned media were cross-linked with 2 mM bis(sulfosoceinimidyl) suberate 
(BS  3) (Pierce Chemical Co., Rockford, IL) for 20 min at 4~  in coated 
tubes. These media were concantrated 50- to 180-fold in Centriprep-30 and 
Centricon-10 concentrator units (Amicon Division, Beverly,  MA) at 4oc. 
Both the ultrafiltration units and membranes were pretreatad with 0.1% BSA 
in PBS. Samples were stored at  -20~ 
To perform Western blots, samples were diluted  1:4 (v/v) in sample 
buffer (10% SDS, 42% glycerol, 180 mM Tris, pH 6.3), boiled for 5 rain, 
and analyzed by SDS-PAGE using 5-16% gradient slabgels. Proteins were 
transferred to  nitrocellulose paper  (0.45-~m  pore  size;  Schleicher and 
Schuell, Keene, NH) for 12 h at 80 V in ice and subjected to immunoblnt- 
ting using 8 #g/ml rabbit anti-LTBP IgG or 8/~g/ml rabbit anti-porcine 
TGF-~I  IgG.  Bound antibodies were visualized using 125I-protein A  fol- 
lowed by autoradiography. 
Immunoblotting of  Platelet LTBP 
50 ng of purified LTBP was run overnight at 8 mA on a 5-16% gradient 
gel. The proteins were transferred to an Immobilon-P membrane (Millipore 
Corp., Bedford, MA) via semidry transfer (1 3/4 h) using the continuous 
buffer system (39 mM glycine, 48 mM tris, 0.0375%  SDS, 20% methanol) 
on the Multiphor II Nova Blot System (Pharmacia LKB Biotechnology, Pis- 
cataway,  NJ). 
The membrane was blocked in blotting buffer (PBS 5 % nonfat dry milk, 
150 mM NaCI, 0.1% Tween-20, 0.02%  azide) for 30 rain and incubated for 
1 h with an antibody prepared against purified platelet LTBP (Ab39) diluted 
1:3,000 in blotting buffer. All dilutions and washes were performed in blot- 
ting buffer except where indicated. After removal of the primary antibody, 
the blot was washed 4  x  15 rain, and goat c~-rabbit IgG-alkaiine phospha- 
tase (Promega Corp., Madison, WI) diluted 1:7,500 was added. After 1 h, 
the blot was washed 8  x  15 rain and 3  x  5 rain in PBS-0.1%  Tween-20. 
The blot was developed for 2 h in BCIP/NBT phosphatase substrate and 
stopped by washing with PBS. 
Preparation of  Conditioned Media 
To prepare homotypic conditioned medium, confluent cultures of the cells 
were trypsinized and seeded separately in either 35-ram plastic dishes or 
24-well Linbro plates (Flow Lab., Inc., McLean, VA) in 10% calf serum 
at a cell density of 8  x  104 BAE and 4  x  104 BSM cells per cm  2. After 
1.5 h  of incubation at 37~  this medium was replaced with 0.1  ml/cm  2 
serum-free ~MEM containing 0.1% BSA. After 5 h, the medium was col- 
lected and centrifuged to remove debris. Conditioned medium from homo- 
typic cultures mixed 1:1 (BAE/BSM cell) was used as a control for medium 
conditioned by heterotypic cultures. 
Heterotypic conditioned medium was prepared by trypsinizing confluent 
cultures of BAE and BSM cells and seeding the two cell types together in 
either 35-ram or 24-well Linbro plates at a call density of 4  ￿  lif  t BAE 
and 2  x  104 BSM cells per cm  2. After 1.5 h of incubation at 37~  this 
medium was replaced with 0.1 ml/cm  2 serum-free r  containing 0.1% 
BSA. After 5 h, the medium was collected and cantrifuged. 
To acid treat conditioned medium, medium was acidified to pH 2.0 with 
HC1 and neutralized after 30 rain at room temperature with NaOH. To acti- 
vate latent TGF-/~ by proteases, conditioned medium was incubated for 2 h 
with plasmin at 370C. After this incubation, subsequent proteolysis was in- 
hibited by the addition of aprotinin (10 ~g/ml). 
Wound Assays for BAE Cell Migration 
Wound assays were performed as previously described (Sato and Rifkin, 
1988).  Briefly,  confluent monolayers of BAE cells in 35-ram dishes were 
wounded with a razor blade. After wounding the cells were washed with 
PBS and further incubated in ccMEM containing 0.1% BSA for 20 h. The 
cells were fixed with absolute methanol after the incubation and stained 
with Giemsa. Cells that had migrated from the edge of the wound were 
counted in successive (seven) 125-#m increments at 100x using a light mi- 
croscope with an ocular grid. The cell number represents the mean from 
at least four different fields. 
~  H-Thymidine Incorporation  Assay 
The inhibition of 3H-thymidine incorporation by CCI 64 mink lung cells 
as an assay for TGF-/~ has been previously described (Tucker et al., 1984). 
Briefly, the CCI 64 calls were trypsinized, centrifuged, and resuspended in 
DME containing 0.2% FCS.  100 #1 of medium containing 8  x  104 cells 
was transferred to a  96-well plate and incubated for 2  h  at  37~  The 
medium was removed from the wells, replaced with the indicated additions, 
and allowed to incubate overnight. The additions were replaced with 100 
#1  of 3H-thymidine (1  /~Ci/ml)  in DME  containing 0.2%  FCS  and in- 
cubated for 2 h at 37~  After this incubation, the cells were fixed with 100 
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twice with 80% methanol, incubated  with 100 #1 of  a 0.5% trypsin solution 
for 30 min, and solubilized with an additional 100 tzl of a 20% solution of 
SDS. The amount of radioactivity that remained associated with the cells 
was quantitated with a Beckman LS3801 beta scintillation counter (Beck- 
man Instruments, Fullerton, CA). 
Plasminogen Activator Assay 
Confluent cultures of BAE ceils grown  in 96-well  plates were preincubated 
in serum-free aMEM for 10 h, and then incubated overnight  with the indi- 
cated additions. After this incubation, the ceils were washed  twice with PBS 
and extracted with 0.5% Triton X-100 in 0.1 M Tris-HC1, pH 8.1. 10 #1 of 
cell extract was assayed for plasminogen activator (PA) activity using a 
125I-fibrin plate assay (Gross et al.,  1982). 
Results 
Detection of  LTBP in Conditioned Media 
To explore the possibility that LTBP is involved in the activa- 
tion of latent TGF-/3 in co-cultures of BAE and BSM cells, 
we first determined whether these cells secreted LTBP and, 
if so, whether this protein occurs in association with a high 
mol wt latent TGF-~ complex. Medium conditioned by equal 
numbers of  either BAE or BSM cells were cross-linked, con- 
centrated and analyzed by SDS-PAGE. Western blot analysis 
of cross-linked conditioned medium using anti-TGF-fl anti- 
body (Fig. 1 A) shows that both BAE and BSM secrete TGF-fl 
as a  high mol wt latent TGF-/3 complex evident as a  band 
migrating with an apparent mol wt of 180,000-205,000. The 
lack of significant reactivity corresponding to lower mol wt 
forms of TGF-fl suggests  that the  vast majority  of TGF-fl 
secreted by BAE and BSM occurs in a high mol wt complex. 
When  a  companion  gel  was  analyzed  by immunoblotting 
using  anti-LTBP  antibody,  bands  were  observed  with  the 
same apparent mol wt as those detected with the anti-TGF-fl 
Figure 1. Western blot of conditioned media from BAE and BSM 
cells probed with anti-TGF-/3  and anti-LTBP IgG. Medium condi- 
tioned by BAE or BSM was  chemically crosslinked using BS  3, 
concentrated, and analyzed by SDS-PAGE under nonreducing con- 
ditions. Proteins were transferred to nitrocellulose paper and probed 
with either (A) anti-TGF-/3, (B) anti-LTBP IgG, or (C) nonimmune 
IgG. Bound antibodies  were visualized  using 125I-Protein A  fol- 
lowed by autoradiography.  Lanes EC contain conditioned medium 
from BAE cells,  lanes SM contain conditioned medium from BSM 
cells,  and lanes T contain 50 ng of rTGF-/31. 
Figure 2. Effect of antibodies to LTBP on generation of  an inhibitor 
of BAE movement in heterotypic cultures.  Confluent  cultures  of 
BAE cells were wounded as described in Experimental Procedures. 
Serum-free media (Control), conditioned media from co-cultures 
of BAE and BSM cells (Co-culture CM), or serum-free media con- 
taining recombinant TGF-/31 (300 pg/ml) (TGF-/3/) were placed on 
the cells.  Nonimmune IgG (200 #g/ml) or anti-LTBP  IgG (200 
#g/ml) were added either directly to the medium (control  and TGF- 
/31) and placed on the wounded BAE monolayer or incubated  with 
the co-cultures (Co-culture CM) for 20 h before being placed on the 
wounded monolayer.  The cells were allowed to migrate overnight, 
and the monolayers were fixed and stained,  and the number of ceils 
that had crossed the original wound margin were counted. Data are 
expressed  as a percent of migration observed in a control untreated 
wound. The average number of  cells that had migrated from the ori- 
gin in the control sample  was  117. 
antibody  (Fig.  1 B).  Incubation of a  sample  of the cross- 
linked  conditioned medium  after  SDS-PAGE with  nonim- 
mune serum yielded no positive bands (Fig. 1 C). Thus, both 
BAE and BSM cells appear to release TGF-fl as a high mol 
wt complex containing LTBP. The relatively narrow distri- 
bution  of molecular  weight  of the  latent  TGF-/3  complex 
when compared to that observed by Miyazono et al.  (1991) 
probably reflects shorter incubation times and the absence of 
serum during our incubation. The absence of any lower mo- 
lecular weight bands in Fig.  1 B suggests that no free LTBP 
is  secreted into the medium by either cell type. 
Anti-LTBP Antibody Inhibits Generation of TGF-fl in 
Heterotypic Cultures 
To test whether LTBP plays a role in the activation of latent 
TGF-fl, the generation of TGF-fl by co-cultures of BAE and 
BSM cells in the presence of antibody to native LTBP was 
monitored. The TGF-fl generated in heterotypic co-cultures 
can  be  quantitated  by the  ability  of the  co-culture  condi- 
tioned medium to block the migration of BAE cells from the 
edge of a wounded monolayer (Sato and Rifldn,  1989; Sato 
et al.,  1990).  Medium conditioned by co-cultures of BAE 
and BSM cells  contains  active TGF-/~ (Fig.  2,  Co-Culture 
CM, row/) as previously demonstrated by receptor competi- 
tion assays (Sato et al.,  1990) and with a TGF-fl neutralizing 
antibody (Antonelli-Orlidge et al.,  1989;  Sato and Rifldn, 
1989).  Medium conditioned by these cell types in the pres- 
ence  of anti-LTBP IgG,  however,  showed  no  evidence  of 
TGF-fl activity (Fig.  2,  Co-Culture  CM,  row 2).  Medium 
conditioned in the presence of nonimmune antibody did con- 
tain TGF-fl activity (Fig.  2,  Co-Culture  CM, row 3).  Anti- 
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from Co-Cultured BAE and BSM Cells in the Presence 
of Various Additions 
Sample  TGF-~/(pg/ml) 
Conditioned medium 
Alone  17  +  1.2 
+LTBP antibody (200 #g/ml)  <2 
+TGF-/3 antibody (50 ttg/ml)  <2 
+ LTBP Fab (50 #g/ml)  <2 
+N.I. antibody (200 t~g/ml)  21  +  1.5 
Acid-treated conditioned medium 
Alone  1,100 + 90 
+LTBP antibody (200/xg/rnl)  1,000 +  172 
Co-cultures of BAE and BSM cells (as described  in Materials and Methods) 
were incubated in ctMEM or with the indicated additions for 6 h, The condi- 
tioned media from the first group of these cultures were transferred  directly 
onto confluent monolayers of BAE cells. The conditioned media from the se- 
cond group of these cultures were acidified to pH 2.0 for 30 rain and neutral- 
ized  before  transfer  onto  confluent  monolayers  of BAE  ceils.  Cells  were 
incubated for 12 h and then extracted in 0.5%  Triton X-100 and assayed for 
PA activity. The amount of TGF-/~ present in the co-culture conditioned medi- 
um  was  calculated  by  reference  to  a  standard  curve  using  recombinant 
TGF-~I. 
LTBP IgG did not affect the movement of BAE cells into a 
denuded area normally observed within 20 h after wounding 
(Fig. 2, Control), nor did anti-LTBP IgG effect the inhibi- 
tory activity of recombinant TGF-/~I on the migration of 
BAE cells (Fig. 2,  TGF-/3, row 2). 
Whereas the inhibition of BAE migration is a sensitive as- 
say for TGF-/3, it requires relatively large volumes of me- 
dium and reagents. The inhibition of PA activity of confluent 
BAE cells by TGF-/3 can be performed in 96-well plates and 
provides a convenient assay for quantitating TGF-/3 genera- 
tion by co-cultured cells.  PA activity in BAE cells is de- 
creased by mature r'I'GF-/31 in a dose-dependent manner with 
an EDs0 of 15-20 pg/ml (Flaumenhaft and Rifkin,  1992). 
The amount of TGF-/~ generated by heterotypic cocultures 
can be determined by quantitating the amount of inhibition 
of PA activity by heterotypic conditioned medium and com- 
paring this to the inhibition of PA activity by standard rTGF- 
/31. Table I shows the amount of TGF-/3 as measured by the 
PA assay generated in the medium of co-cultures of BAE and 
BSM cells incubated in the presence of the indicated addi- 
tions.  The  inhibitory effect of anti-TGF-/3  IgG  indicates 
again that the activity in the co-culture conditioned medium 
is TGF-/3 and that the PA assay under these conditions is 
specific  for TGF-/31. The observation that anti-LTBP IgG 
decreases the amount of TGF-/3 activity in heterotypic cul- 
ture conditioned medium, whereas nonimmune IgG has no 
effect, confirms the data obtained with the migration assay 
(Fig. 2). A Fab fragment derived from the anti-LTBP IgG 
also  inhibited  the  generation  of  TGF-/3 in  co-cultures, 
demonstrating that the antibody does not act by forming 
large aggregates with the LTBP and precipitating the latent 
TGF-/3 from solution (Table  I).  The fact that acid-treated 
conditioned medium from cells co-cultured in the presence 
of anti-LTBP IgG contains at least as much TGF-/3 as control 
co-culture conditioned medium demonstrates that the anti- 
LTBP  IgG  does  not  inhibit the  generation of TGF-/3 by 
preventing the secretion of latent TGF-/3. Inhibition of activa- 
tion of latent TGF-/3 by anti-LTBP IgG occurs in a  dose- 
dependent manner with an EDso of 1-2/~g/ml (Fig. 3). Anti- 
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Figure 3. Dose-dependent  inhibition  of  TGF-/3 generation in hetero- 
typic cultures by LTBP antibody. Co-cultures of BAE and BSM 
cells were incubated in c~MEM  containing the indicated concentra- 
tions of anti-LTBP  IgG for 6 h. The conditioned media from these 
cultures were then transferred onto confluent monolayers of BAE 
ceils for 12 h. After incubation, the cells were extracted in 0.5% 
Triton X-100 and assayed for PA activity. The degree of inhibition 
of PA activity was converted to pg/ml of TGF-fl by reference to a 
standard curve obtained using recombinant "I'GF-/31 added to BAE 
cells. [], anti-LTBP IgG; o, anti-LTBP peptide IgG. 
body raised against a synthetic peptide of LTBP also inhibited 
activation in a dose-dependent manner with an EDs0 of ap- 
proximately 50/~g/ml (Fig. 3).  The difference in potencies 
between the two antibodies is consistent with the observation 
that the peptide antibody has a lower affinity for native LTBP 
than the antibody to the purified protein (data not shown). 
Anti-LTBP IgG Does Not Interfere with Plasmin 
Cleavage of  Latent TGF-:3 or rTGF-:31 Activity 
One mechanism by which anti-LTBP IgG might inhibit the 
activation of latent TGF-/~ in co-culture is to prevent plasmin 
from cleaving the LAP of the latent TGF-/3 complex (Lyons 
et ai., 1990; Sato et ai., 1990). To test this possibility, condi- 
tioned medium from homotypic cultures of BSM cells was 
treated with purified plasmin in the absence or presence of 
anti-LTBP IgG.  A  3H-thymidine incorporation assay was 
used to monitor the generation of active TGF-/~ because the 
presence  of plasmin inhibitors used to  stop the  reaction 
would interfere with the PA assay. Incubation of conditioned 
medium with increasing amounts of plasmin under control 
conditions resulted in a decrease in 3H-thymidine incorpora- 
tion (Fig. 4). This effect was blocked by the inclusion of a 
TGF-/3 neutralizing antibody proving that the decrease in 
DNA synthesis resulted from TGF-/3 generated via plasmin. 
The  addition  of the  LTBP  antibody  to  the  conditioned 
medium before the addition of plasmin did not block the 
plasmin-mediated generation of  TGF-/3. In fact, a slight stim- 
ulation was noted. Nonimmune IgG had a small effect. Thus, 
inhibition of latent TGF-/3 activation by anti-LTBP IgG is not 
the result of inhibition of plasmin cleavage. 
Anti-LTBP IgG might act directly on the mature TGF-/3 
generated in heterotypic conditions. However,  r'I'GF-~I  in- 
hibits PA activity in BAE cells in a dose-dependent manner 
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Figure 4. Effect of anti-LTBP antibody on the generation of active 
TGF-/31 from BSM cell conditioned media by purified plasmin. 
BSM cells were incubated for 20 h in txMEM, and the conditioned 
media were collected. The samples were incubated with plasmin 
(1.0 U/ml unless otherwise noted) either alone or in combination 
with antibody to LTBP (200 #g/ml), nonimmune IgG (200/~g/ml), 
or TGF-B1 IgG (200 #g/ml) for 2 h at 37"C, and then aprotinin (10 
#g/ml) for 15 min. The samples were transferred onto confluent 
monolayers of CC1 64 cells, incubated for 12 h, and assayed for 
3H-thymidine incorporation  as descnlxxl in Materials and Methods. 
equally in the absence or presence of antibody to LTBP (Fig. 
5). Furthermore, although anti-TGF-/3 IgG demonstrates an 
inhibitory effect if added to heterotypic cultures either dur- 
ing or after the medium is conditioned, anti-LTBP IgG only 
inhibits TGF-# activity if added during the conditioning of 
the co-culture medium (data not shown).  Thus, the anti- 
LTBP IgG blocks the generation of  TGF-/3 in heterotypic cul- 
ture but does not directly inhibit the activity of TGF-/$. 
Purified LTBP Inhibits Generation of  Latent TGF-/3 in 
Heterotypic Cultures 
Because the LTBP contains structural motifs that are in- 
volved in protein-protein interactions in other proteins, anti- 
LTBP IgG may inhibit latent TGF-/~ activation by preventing 
the high mol wt latent TGF-# complex from associating with 
a binding site, perhaps on the cell surface. To address this 
possibility, an experiment was conducted in which the ability 
of added free LTBP to inhibit the generation of TGF-/~ by co- 
cultures was determined. The rationale for conducting this 
experiment is that if a binding site for LTBP did exist on the 
cell surface, then free excess LTBP might compete with the 
LTBP in the high molecular weight latent TGF-/~ complex for 
the putative LTBP binding site and inhibit the activation of 
the latent TGF-/3. Thus, the effect of excess free LTBP on la- 
tent TGF-fl activation was determined by quantitating the 
generation of TGF-~ in co-cultures incubated with free ex- 
cess LTBP. 
The amount of LTBP used in initial experiments was at 
least 60-fold greater on a  molar ratio than the estimated 
amount of high molecular weight latent TGF-/3 (1 ng/rnl) in 
heterotypic conditioned medium (Table I). The addition of 
purified free LTBP completely inhibited the generation of 
TGF-/5 in co-cultures of BAE and BSM cells (Fig.  6 A), 
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Figure 5. Effect of anti-LTBP  antibody on inhibition of PA activity 
by recombinant "I'GF-fll.  Confluent cultures of BAE cells were in- 
cubated in aMEM containing the indicated concentrations  of  TGF- 
/31 with or without anti-LTBP IgG (200 #g/ml). After incubation 
the cells were extracted in 0.5% Triton X-100 and assayed for PA 
activity. D, TGF-/~I alone; e, TGF-/31 plus anti-LTBP IgG. 
whereas the addition of free LTBP denatured by boiling for 
15  rain did not. The purified LTBP contained one major 
band as visualized by staining after SDS-PAGE (Fig. 6 B). 
Fig. 7 demonstrates that the inhibition of the generation of 
TGF-~ by LTBP occurred in a dose-dependent manner with 
an ED~0 of •  2  ng/mi of LTBP. Acid treatment of media 
conditioned by heterotypic cultures demonstrated the pres- 
ence of --8 ng/ml of latent TGF-/~ whether the media were 
formed in the absence or presence of excess LTBP. There- 
fore, excess LTBP did not act by inhibiting the secretion of 
latent TGF-~.  Furthermore, excess LTBP did not act by in- 
hibiting the secretion of latent TGF-~. Furthermore, LTBP 
did not inhibit the activity of mature recombinant TGF-~I 
(Fig. 8).  This experiment suggests that the LTBP does not 
directly inhibit TGF-~, but inhibits the generation of mature 
TGF-/~ from the latent complex. 
Discussion 
Activation of  Latent TGF-f3 
TGF-/3 is a potent modulator of cell growth and differentia- 
tion for many cell types (Lyons and Moses,  1990;  Roberts 
and Sporn, 1990; Massague et al., 1990). It is present in se- 
rum and in cell culture conditioned medium at concentra- 
tions well above the levels necessary for the mature form to 
elicit in vitro cellular responses. However, the molecule ex- 
ists primarily as a high tool wt latent complex (Miyazono et 
al.,  1988;  Wakefield et al.,  1988)  from which it must be 
released in order to bind to its cell surfac~ receptor. The 
mechanism by which active TGF-~ is released from the la- 
tent complex is not well understood, but it is assumed that 
this process is important in the regulation of TGF-~ activity 
in vivo. 
Physiological activation of latent TGF-/~ has been pro- 
posed to occur in homotypic cultures of human erythro- 
leukemia cell lines (Piao et al., 1990),  granulosa cell lines 
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purified LTBP. (A) Co-cultures of BAE and BSM cells were incu- 
bated in o~MEM containing no addition, purified LTBP, or heat- 
denatured purified LTBP for 5 h. The conditioned media from these 
cultures and from control BAE and BSM cells were cultured sepa- 
rately, mixed, and then transferred onto confluent monolayers of 
BAE cells and incubated for 12 h. After incubation, the cells were 
extracted in 0.5% Triton X-100 and assayed for PA activity. The 
amount of TGF-fl present in the co-culture medium was calculated 
by reference to a standard curve using recombinant TGF-fll. (B) 
Immunoblot of  purified LTBP.  50 ng of LTBP purified from human 
platelets was analyzed on a 5-16% SDS-polyacrylamide gel, trans- 
ferred to Immobilon-P membrane,  and analyzed with antibody 
Ab39 prepared against purified LTBP. 
plated  on  fibronectin  (Kim  and  Schomberg,  1989),  os- 
teoclasts activated by vitamin A (Oreffo et al., 1989), macro- 
phages exposed to "y-interferon (Twardzik et al., 1990), ker- 
atinocytes treated with retinoic acid (Glick et al., 1989), and 
mammary carcinoma cells and fibroblasts treated with an- 
tiestrogens  (Knabbe  et  al.,  1987;  Colletta  et  al.,  1990). 
Endogenous activation of latent TGF-/5 also occurs in co- 
cultures of BAE and BSM cells (or pericytes) (Antonelli- 
Orlidge et al.,  1989; Sato and Rifldn,  1989). Activation of 
latent TGF-/3 by heterotypic cultures of BAE and BSM cells 
requires cell-to-ceU contact (Antonelli-Orlidge et al., 1989; 
Sato and Rifkin, 1989), binding of  latent TGF-/3 to mannose- 
6-phosphate receptors (Dennis and Rifkin,  1991),  PA and 
plasmin activity (Sato and Rifldn, 1989; Sato et al.,  1990), 
and is complete within 6 h of co-culturing (S. Kojima, un- 
published observation). The concentration of active TGF-/3 
attained in the conditioned medium of co-cultured cells ap- 
pears to be  15-50 pg/rul.  Though this quantity represents 
only 2-5 % of the total latent TGF-/5 present in co-culture 
conditioned medium, it is near or above the EDso of recom- 
binant mature TGF-fl in several assays of  TGF-/3 such as inhi- 
bition  of 3H-incorporation into  CC1  64  mink  lung  cells 
(Tucker et al.,  1984), inhibition of PA activity in BAE cells 
(Flaumenhaft  and  Rifldn,  1992),  and  inhibition  of BAE 
migration (Sato et al.,  1990). Thus, the molecular mecha- 
nism of latent TGF-fl activation remains largely unknown 
even though in vitro systems have been developed in which 
biologically significant amounts of TGF-~5 are produced. 
The activation of latent TGF-fl may resemble the surface 
catalyzed activation of  coagulation factors in which the bind- 
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Figure 7. Dose-dependent inhibition of  TGF-/5  generation in hetero- 
typic culture by purified LTBP.  Co-cultures of BAE and BSM cells 
were  incubated  in  c~MEM containing  increasing  amounts of 
purified LTBP. The conditioned media from these cultures were 
transferred onto confluent monolayers of BAE cells and incubated 
for 12 h. After incubation, the cells were extracted in 0.5% Triton 
X-100 and assayed for PA activity. The amount of TGF-/3 present 
in the co-culture medium was calculated by reference to a standard 
curve using recombinant TGF-/51. 
ing of zymogens and cofactors to specific cell surface mole- 
cules increases the efficiency of activation by orders of mag- 
nitude.  The  activation  of prothrombin  may  be  a  useful 
paradigm  for  latent  TGF-/3  activation  (Furie  and  Furie, 
1988). Prothrombin circulates at relatively high levels com- 
pared to those necessary to initiate coagulation, the inactive 
Effect  of  LTBP  on  rTGF-81  activity 
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Figure 8. Effect of LTBP on the ability of recombinant TGF-/51 to 
induce a decrease in fibrinolytic activity in BAE cells. Confluent 
cultures of  BAE cells were incubated in (xMEM  containing no addi- 
tion,  rTGF-/31 (400 pg/ml), or rTGF-/31 (400 pg/ml) plus LTBP 
(500 ng/ml), After an overnight incubation, the cells were extracted 
in 0.5 % Triton X-100 and assayed for PA activity. 
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prothrombin  to surface activation  complexes of factor X, 
and V.,  and  prothrombin  activation  is,  to a  degree,  self- 
regulating.  Most of these features are repeated in other pro- 
teolytic activation reactions and represent an effective way to 
control extracellular activities. 
Although soluble latent TGF-/~ from conditioned medium 
can be activated by purified plasmin (Lyons et al., 1988), the 
concentrations of plasmin required (1 U/ml) are nonphysio- 
logic. Thus, it is likely that plasmin cleavage of latent TGF-/$ 
occurs on the cell  surface where both latent  TGF-B and 
plasmin can be concentrated and the activity of plasmin en- 
hanced. The concentration of latent TGF-~ on the cell sur- 
face may occur through its association with the cation-inde- 
pendent  mannose-6-phosphate  receptor  (Kovacina  et  al., 
1989; Purchio et al., 1988). Mannose-6-phosphate  and anti- 
mannose-6-phosphate receptor antibody appear to inhibit 
activation by blocking the binding of latent TGF-~ to the cell 
surface (Dennis and Rifldn, 1991). However, the mannose-6- 
phosphate  receptor is  present  at  a  high  concentration  in 
many  cell  types  and  would  not  be  expected  to  confer 
specificity to the activation  reaction.  Furthermore,  latent 
TGF-~ bound to mannose-6-phosphate receptor might be 
rapidly internalized.  Thus, a potential role of the LTBP is to 
target the latent TGF-~ to a molecular assembly responsible 
for the catalytic activation of latent TGF-~. Additionally, the 
LTBP may decrease the rate of internalization of latent TGF-/3 
upon binding  the mannose-6-phosphate  receptor.  We are 
currently testing  this hypothesis. 
It is also worthwhile to consider the significance of the ab- 
solute amount of TGF-/~ formed in these cocultures and its 
possible relevance to in vivo activities.  In the co-culture sys- 
tem only 2-5 % of the total latent TGF-# is found in the acti- 
vated state.  Although  it might  appear  that  a  system that 
generates such a  small  amount of TGF-B is of no conse- 
quence, several considerations  suggest that this level of acti- 
vation may have biological significance. First, LTGF-~I acti- 
vation in the co-culture system is self-regulating  (Sato et al., 
1990); the TGF-B that is formed inhibits subsequent activa- 
tion through  increased expression of plasminogen  activator 
inhibitor 1 (PAI-1)  by both BAEs and SMCs. Thus, once PAI-1 
expression is stimulated  by the TGF-/~ that is initially  pro- 
duced, the cells continue to secrete latent TGF-# but do not 
convert it to TGF-#.  Therefore,  at later times, the ratios of 
active to latent TGF-~I are skewed  by the continuous produc- 
tion of latent TGF-/~. At early time points in the co-culture 
system 20% of the total "I'GF-~ formed may be active  (S. 
Kojima, unpublished observation). Second, the concentra- 
tion of TGF-/~ attained  (20-40 pg/ml)  is  at the EDso for 
many of the biological effects of TGF-~. Third, the interac- 
tions of the LTBP and the mannose-6-phosphate  residues of 
LTGF-~I  with cell surface moieties will increase the local 
concentration of latent TGF-~, and the surface activation will 
enhance the pericellular concentration of the active growth 
factor. The interaction  of TGF-/3 with other matrix and cell 
surface molecules might also produce stimulatory concen- 
trations.  Finally,  if the in vivo response of cells to "I'GF-/3 
mimics the in vitro responses, the activation  of a high per- 
centage of the latent "I'GF-~ would generate TGF-/~I concen- 
trations  10-100-fold  above the EDs0 of the cytokine for its 
receptor condition. This would create a condition in which 
modulation  of TGF-~  effects  would be difficult  as  large 
amounts of active ligand would have to be removed to attain 
the nonstimulated  state. 
Role of tl~ LTBP in the Activation of  Latent TGF-t3 
LTBP has recently been shown to have a role in the proper 
assembly and secretion of TGF-~ (Miyazono  et al.,  1991). 
Tsuji et al.  (1990) have speculated that LTBP may function 
in the activation of latent TGF-/3. Our data indicate a role for 
the LTBP in the activation of latent TGF-B in heterotypic cul- 
tures. Western blot analysis demonstrates that the vast ma- 
jority of latent TGF-/3 secreted by both BAE and BSM cells 
contains the LTBP. Although it is possible that some free la- 
tent TGF-/3 occurs without LTBP, the level of such a species 
must be relatively small to remain undetected in our assay. 
We have observed inhibition of latent TGF-/3 activation by an 
antibody to native platelet LTBP, an antibody to a synthetic 
peptide corresponding to a 12-amino acid sequence within 
the native platelet LTBP, and a Fab fragment of the native 
platelet LTBP antibody. These antibodies probably block ac- 
tivation by preventing a specific domain in LTBP from inter- 
acting with a surface component involved in the formation 
of a  surface complex required for the activation  of latent 
TGF-/~. Inhibition  of activation by addition of excess LTBP 
most likely occurs through competition of exogenous LTBP 
with the LTBP occurring in the high tool wt complex. The 
unlikely possibility that a contaminant in the LTBP prepara- 
tion is inhibiting activation has, however, not been excluded. 
Together these data form strong  support for the hypothesis 
that the LTBP plays an essential role in the activation of latent 
TGF-# in heterotypic cultures. 
Analysis of  the primary structure of human LTBP revealed 
the presence of a number of motifs involved in protein-pro- 
tein interactions  (Kanzaki et al., 1990). Of  particular interest 
with regard  to this  possibility are the multiple  EGF-like 
repeats,  at  least  two of which  contain  a  /~-hydroxylated 
asparagine,  an RGD sequence, and a laminin  B2-1ike se- 
quence.  These sequences are involved in cell surface pro- 
tein-protein interactions  in a variety of molecules (Appella 
et al.,  1988; Ruoslahti and Piersehbacher,  1987; Sasaki and 
Yamada, 1987). In addition,  the LTBP contains three copies 
of a motif with eight eysteine residues.  The organization  of 
the eight cysteine-containing  domains and EGF-like repeats 
has recently also been described in the matrix protein fibril- 
lin (Maslen et al., 1991). Our studies predict that the LTBP 
should interact with a cell surface or matrix macromolecule. 
Although we have some indirect indications  of a cell surface 
or localization of the LTBP, attempts to demonstrate directly 
binding  of LTBP to the cell surface in a saturable manner 
have thus far been unsuccessful due to the fact that we have 
been unable to radiolabel the LTBP to a high specific activ- 
ity. Although it is presently impossible to determine which 
sequences confer this putative targeting  activity on LTBP, 
analysis of rat LTBP revealed neither an RGD sequence nor 
a laminin B2-1ike sequence suggesting that these may not be 
critical to the function of LTBP (Tsuji et al., 1990). Further 
studies on the role of LTBP in the activation of latent TGF-/3 
should determine with what structures the LTBP interacts 
and what parts of the LTBP are involved in this interaction. 
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